y elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so. Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov. There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.
AUXILIUM CONTACTS:
James E. Fickenscher
Chief Financial Officer
+1-484-321-5900
jfickenscher@auxilium.com
or
William Q. Sargent Jr.
Vice-President, Investor Relations and Corporate Communications
+1-484-321-5900
wsargent@auxilium.com
-Tables to Follow-
AUXILIUM PHARMACEUTICALS, INC.Table 1- Condensed Consolidated Statement of Operations(In millions, except per share amounts)(Unaudited)Three Months Ended December 31,Twelve Months EndedDecember 31,2012201120122011Net revenues (1)
$
72.5$
73.3$
395.3$
264.3Operating expenses (2):Cost of goods sold (3)
28.116.578.355.7Research and development
13.218.745.961.9Selling, general and administrative
40.750.1185.5179.9Total operating expenses
81.985.3309.8297.5Income (loss) from operations
90.6(12.0)85.5(33.2)Interest income (expense), net
(0.1)0.20.50.3Net income (loss) (4)
$
90.5$
(11.9)$
85.9$
(32.9)Net income (loss) per common share:Basic
$
.84$
(0.25)$
.76$
(0.69)Diluted
$
.83$
(0.25)$
.74$
(0.69)Shares used to compute net income (loss)per share:Basic
49.248.048.847.9Diluted
49.548.049.347.9(1)
includes revenue recorded as a result of mutual t
'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc. Copyright©2012 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Related biology technology :1.
Auxilium Announces Appointments to Enhance Leadership Team2.
Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference3.
Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference4.
Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference5.
Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference6.
Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 20137.
Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference8.
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting9.
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie10.
Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication11.
MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock